End-of-Year Task: Renewing Your DMT Prescription for 2016

By Kim Dolce—December 8, 2015

December is upon us, and besides being the holiday season, ‘tis also the season to renew our prescriptions for disease-modifying therapies and reapply for co-pay assistance.
Read more »

Labels: Avonex, Betaseron, Copaxone, Gilenya, Rebif

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments

This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY

Read more »

Labels: Aubagio, Betaseron, Copaxone, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

Oral Gilenya (Fingolimod) or Intramuscular Interferon for Relapsing Multiple Sclerosis: STUDY

Read more »

Labels: Gilenya, Plegridy, Study

This Could Be Game-Changing News in the Battle Against Multiple Sclerosis

For a disease that affects more than 400,000 people in the United States and approximately 2.5 million around the globe, multiple sclerosis is arguably not getting its fair share of attention from drug developers and researchers. According to the National Institutes of Health, which has an annual budget near $40 billion, only $115 million is expected to be spent on MS research in 2015.
Read more »

Labels: Aubagio, Daclizumab, Gilenya, Stem Cell, TECFIDERA

MSNZ welcomes consultation period for Tysabri and Gilenya

Read more »

Labels: Betaseron, Copaxone, Gilenya, Tysabri

NOVARTIS WILL PAY TO GET MSers TO USE GILENYA

Novartis will pay out-of-pocket costs for non-Medicare patients who use Gilenya! PLUS:  Novartis will also help patients navigate testing and monitoring recommended by the FDA, paying as much as $600 per patient for that expense.
Read more »

Labels: Avonex, Copaxone, Gilenya, Rebif

Gilyena gets a thumbs-up in Europe to go along with U.S. approval

Read more »

Labels: Gilenya

GOOD NEWS ON TEVA'S NEW MS TREATMENT LAQUINIMOD (NERVENTRA)

Read more »

Labels: Betaseron, Copaxone, Gilenya, Laquinimod (Nerventra), Novantrone, Rebif, Tysabri

Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR

Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone patents to expire starting May 2014. However Biogen are backing the most winners with a staggering $5.8 billion worth of business. 

#1 Glaterimer acetate Teva     $4.3 billion
#2 Avonex Biogen Idec           $3.0 billion
#3 Gilenya Novartis                 $1.9 billion
#4 Tysabri Biogen  Idec           $1.7 billion
#5 Betaseron Bayer                 $1.1 billion
#6 Tecfidera Biogen Idec        $0.9 billion
#7 Rebif EMD serono              $0.6 billion
#8 Ampyra Biogen Idec           $0.3 billion
#9 Aubagio Sanofi                   $0.2 billion
#10 Extavia Novartis               $0.2 billion
Read more »

Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Rebif, TECFIDERA, Tysabri

Data Show Declining Use of Injectables as Oral Multiple Sclerosis Therapies Gain Traction

Read more »

Labels: 100 MOST POPULAR, Aubagio, Copaxone, Gilenya, TECFIDERA

Multiple Sclerosis and Pregnancy: Current Considerations

Read more »

Labels: Betaseron, Copaxone, Gilenya, Pregnancy, Rebif, Tysabri

HOW MS MEDICATIONS DIFFER FROM EACH OTHER

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, TECFIDERA, Tysabri

Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch

Read more »

Labels: Aubagio, Betaseron, Copaxone, Gilenya, TECFIDERA, Tysabri

Tecfidera Is Off to a Quick Start

Read more »

Labels: Aubagio, Copaxone, Gilenya, TECFIDERA

Synthetic Biologics Announces Issuance of U.S. Patent patents for MS and other autoimmune diseases covering the uses of its oral estriol candidate, Trimesta

Read more »

Labels: Betaseron, Copaxone, Extavia, For Doctors, Gilenya, Rebif

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments

This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

15 STUDIES IN FRIDAY'S NEWS

 PLUS: 1590 new Studies we posted from 11/1 to Thursday 2/12 Start at the Bottom!

The NBSS, developed specifically to assess the symptoms and consequences associated with neurogenic bladder dysfunction, has appropriate psychometric properties. Depending on the measurement need, individual domains may be selected, or it can be used as a comprehensive score.

Read Study at Pubmed.gov

The fraction of intrathecally-produced VZV-specific IgG of the total intrathecally produced IgG discriminates between patients with VZV reactivation and MS. Our results provide further evidence that intrathecally-produced VZV antibodies are part of the polyspecific immune response in patients with MS.

Read study at Pubmed.gov

 In addition to autoantigens implicated in thyroid autoimmunity, fibrocytes and derivative fibroblasts express multiple autoantigens associated with T1DM. This expression results from active gene promoters and abundant steady-state mRNA encoding ICA69 and IA-2. These latest findings demonstrate that fibrocytes express antigens relevant to multiple forms of endocrine autoimmunity. They suggest the potential for these cells playing a direct role in immune reactivity directed at the thyroid and pancreatic islets.

Read Study at Pubmed.gov

MMPs can also enhance the cleavage of myelin basic protein (MBP) and the demyelination process. Regarding the growing data on the roles of MMPs and their tissue inhibitors (TIMPs) in the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.

Read Study at Pubmed.gov

In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.
Read Study Pubmed.gov

Read more »

Labels: 500 BEST PML STORIES & STUDIES, Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, PML (Progressive Multifocal Leukoencephalopathy), Rebif, Sativex, TECFIDERA, Tysabri

15 STUDIES IN MONDAY'S NEWS

 PLUS: 1530 new Studies we posted from 11/1 to Sunday 2/9 Start at the Bottom!

Farming and exposure to livestock may be important factors in the development of FCD among women, with this finding further revealed after the confounding effect of parity or number of children is considered.
Read Study at Pubmed.gov

Results suggest that demyelinated lesions in MS mainly have a remote effect on the thalamus and that the measurement of CBF using ASL could be an objective marker for monitoring disease activity in MS.
Read Study at Pubmed.gov

Here, we summarize currently accepted therapeutic principles and the drugs in late stages of development, as well as spotlighting potential novel openings for future research.
Read Study at Pubmed.gov

Collaboration between neurologists and psychiatrists whilst caring for patients displaying neuropsychiatric manifestations of MS is crucial to enable more accurate diagnoses and try to improve treatment and overall prognosis. 
Read Study at Pubmed.gov

In summary, in this retrospective analysis, daclizumab therapy substantially decreased the rate of brain atrophy in relapsing-remitting MS in comparison to other disease-modifying therapies, predominantly interferon β.
Read Study at Pubmed.gov

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, Sativex, TECFIDERA, Tysabri

15 STUDIES IN SUNDAY'S NEWS

 PLUS: 1515 new Studies we posted from 11/1 to Saturday 2/8 Start at the Bottom!


In this paper we present a new unsupervised approach addressing this problem with dictionary learning and sparse coding methods. We show its general applicability to the problem of lesion segmentation by evaluating our approach on synthetic and clinical image data and comparing it to state-of-the-art methods.
Read Study at Pubmed.gov

In this paper we will review the substantial literature regarding experimental and clinical use of these stem cells and possible mechanisms in the treatment of MS. These results may pave the road for the utilization of stem cells for the treatment of MS.
Read Study at Pubmed.gov

Long walking tests and patient-reported MSWS-12 were more appropriate than short walking tests in detecting clinically meaningful improvement after physical rehabilitation, particularly the MSWS-12 for moderate to severely disabled pwMS.
Read Study at Pubmed.gov

The use of patient self-assessed outcome measures that appraise the quality of diagnosis communication is also important to allow health services to understand and meet the needs and preferences of PwMS.
Read Study at Pubmed.gov

Quantitative gait assessment reveals subtle gait disorders in patients with low disability of relapsing-remitting multiple sclerosis. The impact of different cognitive domains on gait induces specific gait disturbances that highlight the strong interaction between gait and cognition.
Read Study at Pubmed.gov

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, Sativex, TECFIDERA, Tysabri

15 STUDIES IN SATURDAY'S NEWS

 PLUS: 1500 new Studies we posted from 11/1 to Friday 2/7 Start at the Bottom!


Studies are needed to further clarify why suicide ideation and suicidal behavior are associated with neurological diseases, in order to improve quality of life, alleviate patient distress, and prevent nonfatal and fatal suicide attempts in veteran and non-veteran populations.
Read Study at Pubmed.gov

Obesity in childhood or adolescence is associated with an increased risk of pediatric-onset and adult-onset multiple sclerosis
Read Study at Pubmed.gov

Autoimmune disorders are rare, but some of them tend to occur together with MS at a higher rate than in controls. Although women are generally more prone to ADs than men, significantly increased occurrence of other ADs were only found in male MS patients.
Read Study at Pubmed.gov

Paternal MS and MS-related clinical factors were not significantly associated with birth outcomes (p>0.05). This study provides assurance to expecting fathers with MS and their families.
Read Study at Pubmed.gov

This study showed that PET imaging of demyelination and remyelination processes in focal lesions is feasible.
Read Study at Pubmed.gov

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, Sativex, TECFIDERA, Tysabri